Breaking News, Collaborations & Alliances

AbbVie, Umoja Biopharma Enter CAR-T Cell Therapies Collaboration

Abbvie to pay up to $1.44B to leverage Umoja's VivoVec gene delivery platform to develop in-situ generated oncology candidates.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie and Umoja Biopharma, an early clinical-stage biotechnology company, entered two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology using Umoja’s VivoVec platform.   The first agreement provides AbbVie an exclusive option to license Umoja’s CD19 directed in-situ generated CAR-T cell therapy candidates, including UB-VV111, Umoja’s lead clinical program for hematologic malignancies currently at the IND-e...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters